Table A1.
Cycle or Dose Variable | No. (%) of Patients |
|
---|---|---|
Trabectedin (n = 340) | Dacarbazine (n = 155) | |
Total with at least two cycles | 298 (88) | 125 (81) |
Cycle delay | ||
Yes | 193 (57) | 62 (40) |
No | 105 (31) | 63 (41) |
No. of cycle delays | ||
1 | 96 (28) | 35 (23) |
2 | 37 (11) | 13 (8) |
3 | 27 (8) | 8 (5) |
4 | 12 (4) | 1 (1) |
≥ 5 | 21 (6) | 5 (3) |
Dose reduction | ||
Yes | 119 (35) | 15 (10) |
No | 179 (53) | 110 (71) |
No. of dose reductions | ||
1 | 83 (24) | 13 (8) |
2 | 36 (11) | 2 (1) |
NOTE. Cycle delays and dose reductions were tabulated for patients who received at least two cycles of treatment.